These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31922613)

  • 1. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy.
    Muley SA; Jacobsen B; Parry G; Usman U; Ortega E; Walk D; Allen J; Pasnoor M; Varon M; Dimachkie MM
    Muscle Nerve; 2020 May; 61(5):575-579. PubMed ID: 31922613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained remission of CIDP associated with Evans syndrome.
    Knecht H; Baumberger M; Tobòn A; Steck A
    Neurology; 2004 Aug; 63(4):730-2. PubMed ID: 15326255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.
    Cocito D; Grimaldi S; Paolasso I; Falcone Y; Antonini G; Benedetti L; Briani C; Fazio R; Jann S; Matà S; Sabatelli M; Nobile-Orazio E;
    Eur J Neurol; 2011 Dec; 18(12):1417-21. PubMed ID: 21819489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic inflammatory demyelinating polyradiculoneuropathy].
    Franques J; Azulay JP; Pouget J; Attarian S
    Rev Med Interne; 2010 Jun; 31(6):411-6. PubMed ID: 20395023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy.
    Fatehi F; Okhovat AA; Panahi A; Ziaaddini B; Rajabally YA; Nafissi S
    J Peripher Nerv Syst; 2021 Dec; 26(4):469-474. PubMed ID: 34469032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    Hu J; Sun C; Lu J; Zhao C; Lin J
    J Neurol; 2022 Mar; 269(3):1250-1263. PubMed ID: 34120208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy.
    D'Amico A; Catteruccia M; De Benedetti F; Vivarelli M; Colucci M; Cascioli S; Bertini E
    Eur J Paediatr Neurol; 2012 May; 16(3):301-3. PubMed ID: 21903431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
    Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic inflammatory demyelinating polyneuropathy: Plasmapheresis or cyclosporine can be good treatment options in refractory cases.
    Kim W; Shim YK; Choi SA; Kim SY; Kim H; Lim BC; Hwang H; Choi J; Kim KJ; Chae JH
    Neuromuscul Disord; 2019 Sep; 29(9):684-692. PubMed ID: 31473049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Modern aspects of diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy in children].
    Kozyreva AA; Bembeeva RT; Druzhinina ES; Zavadenko NN; Kolpakchi LM; Pilia SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):58-68. PubMed ID: 38465811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CIDP variants in diabetes: measuring treatment response with a small nerve fiber test.
    Névoret ML; Vinik AI
    J Diabetes Complications; 2015 Mar; 29(2):313-7. PubMed ID: 25466645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic inflammatory axonal polyneuropathy.
    Oh SJ; Lu L; Alsharabati M; Morgan MB; King P
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1175-1180. PubMed ID: 32917820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pure sensory chronic inflammatory polyneuropathy: rapid deterioration after steroid treatment.
    Chroni E; Veltsista D; Gavanozi E; Vlachou T; Polychronopoulos P; Papathanasopoulos P
    BMC Neurol; 2015 Mar; 15():27. PubMed ID: 25885891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study.
    Vanhoutte EK; Latov N; Deng C; Hanna K; Hughes RA; Bril V; Dalakas MC; Donofrio P; van Doorn PA; Hartung HP; Merkies IS
    Eur J Neurol; 2013 May; 20(5):748-55. PubMed ID: 22891893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
    Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
    Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases.
    Roux T; Debs R; Maisonobe T; Lenglet T; Delorme C; Louapre C; Leblond V; Viala K
    J Peripher Nerv Syst; 2018 Dec; 23(4):235-240. PubMed ID: 30203907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.